Shanghai Labway Clinical Laboratory Co., Ltd

Equities

301060

CNE100004RG8

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. 23:00:00 23/05/2024 BST 5-day change 1st Jan Change
9.94 CNY -1.58% Intraday chart for Shanghai Labway Clinical Laboratory Co., Ltd -3.31% -25.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023. CI
Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023. CI
Shanghai Labway Clinical Laboratory Co., Ltd announces an Equity Buyback for CNY 30 million worth of its shares. CI
Shanghai Labway Clinical Laboratory Co., Ltd authorizes a Buyback Plan. CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of Shanghai Labway Clinical Laboratory Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2023. CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Labway Clinical Laboratory to Buy Enterprise Management Firm For 283 Million Yuan MT
Shanghai Labway Clinical Laboratory Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023 CI
Shanghai Labway Clinical Laboratory Co., Ltd Approves Cash Dividend for 2022 CI
Shanghai Labway Clinical Laboratory Co., Ltd Proposes Final Cash Dividend for the Year 2022 CI
Shanghai Labway Clinical Laboratory Co., Ltd cancelled the transaction announced on September 1, 2022 CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
As China seeks to live with the virus, COVID-control industries face decline RE
Chinese COVID testing firms report big profits as virus fight intensifies RE
Shanghai Labway Clinical Laboratory Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shanghai Labway Clinical Laboratory Co., Ltd.(XSEC:301060) added to S&P Global BMI Index CI
Certain A Shares of Shanghai Labway Clinical Laboratory Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2022. CI
Shanghai Labway Plans $96 Million Share Sale to Fund New Laboratories MT
Shanghai Labway Clinical Laboratory Co., Ltd. announced that it expects to receive CNY 664.4942 million in funding CI
Shanghai Labway Clinical Laboratory Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Jiangsu Xikang Technology Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Labway Clinical Laboratory Co., Ltd CI
Chart Shanghai Labway Clinical Laboratory Co., Ltd
More charts
Shanghai Labway Clinical Laboratory Co Ltd is a company providing overall solutions for the inspection and diagnosis industry. The Company's businesses include medical testing and pathological diagnosis services and the sales of in vitro diagnosis product. The medical examination and pathological diagnosis services include pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination and physical and chemical examination. The in vitro diagnostic products sales include in vitro diagnostic instruments, reagents and related accessories and consumables.
More about the company
  1. Stock Market
  2. Equities
  3. 301060 Stock
  4. News Shanghai Labway Clinical Laboratory Co., Ltd
  5. Shanghai Labway Plans $96 Million Share Sale to Fund New Laboratories